## 3-O-Methyldopa-d<sub>3</sub> hydrate

Cat. No.:	HY-113468AS1	
Molecular Formula:	C <sub>10</sub> H <sub>12</sub> D <sub>3</sub> NO <sub>5</sub>	
Molecular Weight:	232.25	
Target:	Dopamine Receptor; Endogenous Metabolite; Isotope-Labeled Compounds	D
Pathway:	GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease; Others	<sup>-</sup> D <sub>HO</sub> <sup>-</sup> NH <sub>2</sub>
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	H <sub>2</sub> O

Inhibitors

**Product** Data Sheet

BIOLOGICAL ACTIV		
Description	3-O-Methyldopa-d <sub>3</sub> (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of I-DOPA and dopamine[1].	
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potentia affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

## REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Masato Asanuma, et al. 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA. BMC Neurosci. 2016 Jul 25;17(1):52.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA



E-mail: tech@MedChemExpress.com